Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.

@article{Bruix2001ClinicalMO,
  title={Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.},
  author={Jordi Bruix and Morris Sherman and Josep M. Llovet and Michel Beaugrand and Riccardo Lencioni and Andrew K. Burroughs and Erik Christensen and Luigi Pagliaro and Massimo Colombo and Juan Rodés},
  journal={Journal of hepatology},
  year={2001},
  volume={35 3},
  pages={
          421-30
        }
}

Figures and Tables from this paper

Resection for hepatocellular carcinoma: Is it justifiable to restrict this to the American Association for the Study of the Liver/Barcelona Clinic for Liver Cancer criteria?
  • P. Chow
  • Medicine
    Journal of gastroenterology and hepatology
  • 2012
TLDR
The AASLD Guidelines have evolved from the guidelines of the Barcelona Clinic for Liver Cancer (BCLC), and are significantly more conservative with regard to surgical resection compared with the APASL Guidelines, which reflect the two extremes of a spectrum of existing consensus opinions.
Assessment of treatment response in hepatocellular carcinoma: a review of the literature.
TLDR
This brief review is to compare data in literature regarding the application and the performance of mRECIST in clinical practice, and to discuss unclear and open issues.
Liver transplantation for hepatocellular carcinoma in clinical practice: the lesson from a 20-year multicentre experience in Italy
TLDR
Among patients with HCC, those undergoing LT represent a small minority; even fewer are those who undergo transplantation according to AASLD guidelines, adherence to which only marginally affects survival; overall, LT impact on HCC patients’ treatment is very limited.
Hepatocellular carcinoma treatment strategies - a case-based review
TLDR
This tumor is remarkable because it occurs mostly superimposed on chronic liver diseases, which entails the need to take special attention to liver function preservation and hepatotoxicity prevention when choosing a specific therapy.
The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines from 2001 to 2017.
TLDR
Comparison of current guidelines published from January 2001 to June 2017 worldwide with a focus on the clinical management of HCC found that more straightforward or refined guidelines would help guide doctors to make better decisions in the treatment of H CC in the future.
Grey zone in the Barcelona Clinic Liver Cancer Classification for hepatocellular carcinoma: Surgeons' perspective.
TLDR
From the surgeons' perspectives, some comments on the BCLC classification concerning subjectivity of the assessment criteria, comprehensiveness of the staging definition and accuracy of the therapeutic recommendations are put forward.
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008.
TLDR
There is now robust evidence in favour of systemic therapy with sorafenib in patients with advanced HCC with preserved liver function, and those involved in the care for patients with HCC should be encouraged to participate in well-designed clinical trials, to increase evidence-based knowledge and to make further progress.
Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Manual Proposed by the Japan Society of Hepatology
TLDR
The Japan Society of Hepatology (JSH) published the Consensus-Based Clinical Practice Manual in 2007, and the content of this manual, especially issues on surveillance, diagnosis, staging, and treatment, is summarized.
Clinico-pathological aspects in hepatocellular carcinoma
TLDR
Hepatocellular carcinoma was predominantly associated with chronic HBV-infection and hepatomegaly was the most frequently sign of HCC in patients enrolled in this study.
...
...

References

SHOWING 1-10 OF 144 REFERENCES
Surgical resection versus transplantation for early hepatocellular carcinoma: clues for the best strategy
TLDR
Most hepatologists now favor orthotopic liver transplantation (OLT) as the preferred option for early HCC, and more recent data have shown that the restriction of OLT to patients with single tumors less than 5 cm or with three nodules will result in 5-year survival rates of around 70%.
Hepatocellular carcinoma in Italian patients with cirrhosis.
TLDR
In the West, as in Asia, patients with cirrhosis of the liver are at substantial risk for hepatocellular carcinoma, with a yearly incidence rate of 3 percent, and the screening program did not appreciably increase the rate of detection of potentially curable tumors.
Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in Western patients with cirrhosis
TLDR
In Western patients with cirrhosis, a limited number of usual variables can identify a group of patients at high risk for HCC requiring intensive screening or preventive measures.
A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients
TLDR
The aims of this study were to verify the value of known prognostic factors and to devise a prognostic index more sensitive than the commonly used Okuda stage, and to produce a new prognostic system that accounts for both liver function and tumor characteristics.
Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis
TLDR
The authors' surveillance policy of patients with LC requires a large number of resources and offers little benefit in terms of patient survival, and the decision whether to adopt a surveillance policy towards HCC should rely on the prevalence of the disease in the population and on the resources of a particular country.
Liver cell dysplasia is a major risk factor for hepatocellular carcinoma in cirrhosis: a prospective study.
Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials.
TLDR
This systematic review of RCTs on HCC indicates that the non-surgical current treatments are ineffective or minimally and uncertainly effective and can deserve further assessment by larger and methodologically more sound randomized trials.
Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes
TLDR
Consideration should be given to careful screening for HCC in male PBC patients with cirrhosis, as it is a relatively rare complication of cirrhotic PBC in women and is poorly predicted by prognostic models.
...
...